New antibiotic agents for bloodstream infections

Fowler, 2006, Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, 355, 653, 10.1056/NEJMoa053783 Falagas, 2007, Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence, J Antimicrob Chemother, 60, 7, 10.1093/jac/dkm137 Poutsiaka, 2007, Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients, J Infect, 54, 567, 10.1016/j.jinf.2006.11.007 Segreti, 2006, Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients, Pharmacotherapy, 26, 347, 10.1592/phco.26.3.347 Shorr, 2005, Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies, J Antimicrob Chemother, 56, 923, 10.1093/jac/dki355 Birmingham, 2003, Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program, Clin Infect Dis, 36, 159, 10.1086/345744 Falagas, 2008, Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials, Lancet Infect Dis, 8, 53, 10.1016/S1473-3099(07)70312-2 Drew, 2000, Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group, J Antimicrob Chemother, 46, 775, 10.1093/jac/46.5.775 Moellering, 1999, The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency-Use Study Group, J Antimicrob Chemother, 44, 251, 10.1093/jac/44.2.251 Raad, 2005, Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens, Clin Infect Dis, 40, 374, 10.1086/427283 Chambers, 2005, Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus, Antimicrob Agents Chemother, 49, 884, 10.1128/AAC.49.3.884-888.2005 Mushtaq, 2004, Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases, Antimicrob Agents Chemother, 48, 1313, 10.1128/AAC.48.4.1313-1319.2004 Fritsche, 2005, Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003), Clin Microbiol Infect, 11, 974, 10.1111/j.1469-0691.2005.01271.x Chastre, 2008, Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study, Crit Care Med, 36, 1089, 10.1097/CCM.0b013e3181691b99 Jones, 2004, Activities of doripenem (S-4661) against drug-resistant clinical pathogens, Antimicrob Agents Chemother, 48, 3136, 10.1128/AAC.48.8.3136-3140.2004 Reinert, 2007, Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline, J Antimicrob Chemother, 60, 1018, 10.1093/jac/dkm310 Peleg, 2007, Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report, J Antimicrob Chemother, 59, 128, 10.1093/jac/dkl441 Maroko, 2007, Results of Phase 3 study comparing a tigecycline (TGC) regimen with an imipenem/cilastatin (IMI) regimen in treatment of patients (Pts) with hospital-acquired pneumonia (HAP) Karageorgopoulos, 2008, Tigecycline for the treatment for multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence, J Antimicrob Chemother, 62, 45, 10.1093/jac/dkn165 Falagas, 2005, Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections, Clin Infect Dis, 40, 1333, 10.1086/429323 Falagas, 2006, Toxicity of polymyxins: a systematic review of the evidence from old and recent studies, Crit Care, 10, R27, 10.1186/cc3995 Kasiakou, 2005, Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis, Antimicrob Agents Chemother, 49, 3136, 10.1128/AAC.49.8.3136-3146.2005 Falagas, 2007, When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach, Shock, 27, 605, 10.1097/01.shk.0000246899.73315.cb Reynolds, 2007, Resistance in Pseudomonas aeruginosa and Acinetobacter spp. from blood in the UK and Ireland, 2001–2005 Korbila, 2007, Antibiotic-lock therapy for long-term catheter-related bacteremia: a review of the current evidence, Expert Rev Anti Infect Ther, 5, 639, 10.1586/14787210.5.4.639 Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters, Drugs, 65, 2499, 10.2165/00003495-200565170-00006 Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials, Lancet Infect Dis, 5, 581, 10.1016/S1473-3099(05)70218-8